Chengyi Pharmaceutical (603811.SH) released its first quarter performance, with a net profit attributable to the parent company of 45.7932 million yuan, a year-on-year increase of 40.1%.

Zhijing Finance APP news, Chengyi Pharmaceutical (603811.SH) released the first quarter report for 2025, with the company's first quarter operating income of 186 million yuan, a year-on-year increase of 21.26%; the net profit attributable to the shareholders of the listed company was 45.7932 million yuan, a year-on-year increase of 40.10%; the net profit attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 45.3286 million yuan, a year-on-year increase of 46.74%; basic earnings per share were 0.14 yuan per share.